PERRIGO Co plc (PRGO) revenue by segment
PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 9/3010% below fair value
$16.94+1.18 (+7.49%)
Close on Nov 18, 2026Market cap $2.35BP/E –Yield 6.85%
Doanh thu theo bộ phận của PERRIGO Co plc
Periods
Theo bộ phận kinh doanh
| Doanh thu | FY2025CY2025 | FY2024CY2024 | FY2023CY2023 | FY2022CY2022 | FY2021CY2021 | FY2020CY2020 | FY2019CY2019 | FY2018CY2018 | FY2017CY2017 | FY2015CY2015 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CSCA | $2.59B | $2.69B | $2.96B | $2.93B | $2.69B | $2.69B | $2.49B | $2.41B | $2.43B | – | 60.8% | -4.0% |
| CSCI | $1.67B | $1.68B | $1.69B | $1.53B | $1.45B | $1.40B | $1.38B | $1.40B | $1.41B | – | 39.2% | -0.7% |
| RX Pharmaceuticals | – | – | $0 | $0 | $0 | $0 | $0 | $920.80M | $1.05B | $936.00M | – | – |
| Segment Reconciling Items | – | – | – | – | – | – | $0 | $0 | – | $0 | – | – |
| Other(1) | – | – | – | – | – | – | $0 | $0 | $55.70M | $107.70M | – | – |
| Other | – | – | – | – | – | – | $0 | $0 | $55.70M | – | – | – |
| CHCI | – | – | – | – | – | – | – | $1.50B | $1.49B | $704.60M | – | – |
| CHCA | – | – | – | – | – | – | – | $2.41B | $2.43B | $2.48B | – | – |
| Specialty Sciences | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| RX | – | – | – | – | – | – | – | – | – | $936.00M | – | – |
| All Countries Domain | – | – | – | – | – | – | – | – | – | $4.60B | – | – |
| All Countries | – | – | – | – | – | – | – | – | – | $4.23B | – | – |
| Lợi nhuận hoạt động | FY2025CY2025 | FY2024CY2024 | FY2023CY2023 | FY2022CY2022 | FY2021CY2021 | FY2020CY2020 | FY2019CY2019 | FY2018CY2018 | FY2017CY2017 | FY2015CY2015 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CSCI | -$228.80M | $105.00M | -$35.20M | -$30.00M | $36.10M | $32.30M | $19.60M | $6.80M | -$2.70M | – | -317.9% |
| CSCA | -$669.00M | $269.90M | $389.60M | $366.10M | $206.50M | $465.00M | $406.70M | $174.40M | $470.90M | – | -347.9% |
| RX Pharmaceuticals | – | – | $0 | $0 | $0 | $0 | $0 | $214.60M | $306.10M | $364.70M | – |
| Segment Reconciling Items | – | – | – | – | – | – | -$231.40M | -$159.30M | -$175.60M | -$121.50M | – |
| Other(1) | – | – | – | – | – | – | $0 | $0 | $8.70M | $26.80M | – |
| CHCI | – | – | – | – | – | – | – | $16.50M | $12.50M | $38.20M | – |
| CHCA | – | – | – | – | – | – | – | $147.60M | $445.00M | $381.90M | – |
| Specialty Sciences | – | – | – | – | – | – | – | – | $0 | -$17.60M | – |
| RX | – | – | – | – | – | – | – | – | – | $364.70M | – |
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025CY2025 | FY2024CY2024 | FY2023CY2023 | FY2022CY2022 | FY2021CY2021 | FY2020CY2020 | FY2019CY2019 | FY2018CY2018 | FY2017CY2017 | FY2015CY2015 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contract Manufacturing | $270.90M | $306.20M | $337.30M | $350.10M | $299.70M | $261.40M | $285.30M | $300.50M | – | – | 6.4% | -11.5% |
| Active pharmaceutical ingredients | – | – | – | – | – | – | – | $0 | $55.60M | – | – | – |
Theo khu vực
| Doanh thu | FY2025CY2025 | FY2024CY2024 | FY2023CY2023 | FY2022CY2022 | FY2021CY2021 | FY2020CY2020 | FY2019CY2019 | FY2018CY2018 | FY2017CY2017 | FY2015CY2015 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.54B | $2.65B | $2.92B | $2.87B | $2.57B | $2.58B | $2.36B | $3.10B | $3.27B | $3.30B | 59.7% | -4.1% |
| Europe | $1.62B | $1.60B | $1.62B | $1.47B | $1.39B | $1.35B | $1.34B | $1.35B | $1.34B | $576.40M | 38.0% | +0.7% |
| All other countries | $96.70M | $119.50M | $116.30M | $107.30M | $179.80M | $158.60M | $173.80M | $285.80M | $330.30M | $340.30M | 2.3% | -19.1% |
| Ireland | $42.10M | $39.60M | $40.80M | $29.30M | $23.70M | $29.80M | $23.40M | $25.70M | $30.40M | $7.20M | 1.0% | +6.3% |
| Outside United States | – | – | – | – | – | – | – | – | – | $340.30M | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Perrigo (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Perrigo, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?